Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Accenture
Deloitte
McKesson
Johnson and Johnson
Federal Trade Commission
Citi
Novartis
US Army
QuintilesIMS

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020725

« Back to Dashboard

NDA 020725 describes CREON, which is a drug marketed by Abbvie and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the CREON profile page.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
Summary for 020725
Tradename:CREON
Applicant:Abbvie
Ingredient:pancrelipase (amylase;lipase;protease)
Patents:1
Suppliers and Packaging for NDA: 020725
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725 NDA AbbVie Inc. 0032-1203 0032-1203-70 1 BOTTLE in 1 CARTON (0032-1203-70) > 70 CAPSULE, DELAYED RELEASE in 1 BOTTLE
CREON pancrelipase (amylase;lipase;protease) CAPSULE, DELAYED RELEASE;ORAL 020725 NDA AbbVie Inc. 0032-1203 0032-1203-64 1 BOTTLE in 1 CARTON (0032-1203-64) > 70 CAPSULE, DELAYED RELEASE in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength30,000USP UNITS;6,000USP UNITS;19,000USP UNITS
Approval Date:Apr 30, 2009TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 7, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength60,000USP UNITS;12,000USP UNITS;38,000USP UNITS
Approval Date:Apr 30, 2009TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 7, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED RELEASE;ORALStrength120,000USP UNITS;24,000USP UNITS;76,000USP UNITS
Approval Date:Apr 30, 2009TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 7, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
US Department of Justice
McKesson
Novartis
Dow
Citi
Medtronic
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot